Premarin WHI Results May Mean Additional Label Changes, FDA Says

The findings could lead FDA to revise the class labeling for hormone therapies to reflect the absence of risk of heart disease and invasive breast cancer among estrogen-only patients.

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Archive

More from Pink Sheet